Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2014
  • Initiating Organization: NIH Rare Disease Clinical Research Network
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
    Ftld Syndromes
  • Location: North America

Abstract

The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) consortium is an integrated group of academic medical centers partnered with patient support organizations and dedicated to conducting clinical research in sporadic and familial frontotemporal lobar degeneration (FTLD) syndromes. ARTFL is funded by the National Institutes of Health (NIH) and is part of the Rare Diseases Clinical Research Network (RDCRN). Its operations are based at the University of California, San Francisco, and there are currently 14 clinical study sites in the United States and Canada.

Mission

ARTFL’s mission is to conduct clinical research to learn more about the different FTLD spectrum diseases to support the development of new therapies and diagnostic tools. It also aims to assist patients and family members to manage these diseases by connecting them with patient advocacy groups, expert medical care, support services, and new research opportunities in particular clinical trials.

The goals of this consortium are as follows:

Consortium History

October 2014: ARTFL funding by RDCRN announced

Structure & Governance

This consortium is part of the RDCRN, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS). The RDCRN is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment, and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.

Funding and scientific oversight for the RDCRN are provided by NCATS and 10 NIH components: Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; the National Heart, Lung and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; and Office of the Director. In addition, patient advocacy groups provide funds for many of the projects.

Financing

The generous support of the NIH has provided ARTFL with the resources necessary to create this ongoing clinical research infrastructure.

Points of Contact

Caitlin Glennon
University of California, San Francisco
Memory and Aging Center
675 Nelson Rising Lane
Suite 190, Box 1207
San Francisco, CA 94158
phone: 415-476-0662
email: cglennon@memory.ucsf.edu

Sponsors & Partners

Columbia University

Johns Hopkins University School of Medicine

Massachusetts General Hospital

Mayo Clinic, Jacksonville, FL

Mayo Clinic, Rochester, MN

Northwestern University

University of British Columbia

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of North Carolina Chapel Hill

University of Pennsylvania

University of Toronto

Washington University, St. Louis


Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.